Monocyte-derived dendritic cells from HCV-infected patients transduced with an adenovirus expressing NS3 are functional when stimulated with the TLR3 ligand poly(I:C)
/in Chronic Virus Hepatitis, International Publications /von 2008-07-10 / J. Viral Hepat. 2008 Nov;15(11):782-9Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2
/in Breast Cancer, Dendritic Cells, International Publications /von 2008-07-09 / Vaccine 2008 Aug;26(36):4716-24Dendritic cell vaccination with xenogenic polypeptide hormone induces tumor rejection in neuroendocrine cancer
/in Dendritic Cells, International Publications, Thyroid Cancer /von 2008-07-01 / Clin. Cancer Res. 2008 Jul;14(13):4298-305CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo
/in Hepatocellular Carcinoma, International Publications /von 2008-07-01 / Hepatology 2008 Jul;48(1):157-68Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells
/in Breast Cancer, International Publications /von 2008-07-01 / J. Immunol. 2008 Jul;181(1):808-21Regional hyperthermia in high-risk soft tissue sarcomas
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2008-07-01 / Curr Opin Oncol 2008 Jul;20(4):438-43Maximizing dendritic cell migration in cancer immunotherapy
/in Dendritic Cells, International Publications /von 2008-07-01 / Expert Opin Biol Ther 2008 Jul;8(7):865-74Strategies to overcome obstacles to successful immunotherapy of melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-500Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
/in International Publications, Malignant Melanoma /von 2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-51
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de